Javascript must be enabled to continue!
Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
View through CrossRef
Introduction: BCR-ABL1-negative myeloproliferative disorders are a sub-group of myeloproliferative neoplasms (MPNs) that consist of polycythemia Vera (PV), Essential thrombocythemia (ET) and Primary Myelofibrosis (PMF). Over the past decade, the morphological and clinical division of myeloproliferative neoplasms (MPN) has changed to a classification that describes the molecular heterogeneity and is unique to this subgroup of haematological malignancies. This includes alterations in Janus kinase 2 (JAK2), and MPL genes.
Objective: To determine the frequency of JAK2 (p.V617F) and MPL (p.W515L) mutation in primary myelofibrosis in KPK province of Pakistan.
Methodology: Fifty patients with PMF were enrolled in the study. JAK2 mutation status was determined using allele specific primers and MPL mutation was detected by direct Sanger sequencing technique. The data was analyzed using BioEdit by aligning the sequence data with reference genome hg19 assembly.
Results: Among 50 patients, 41 patients were diagnosed with PMF, while 9 patients had secondary myelofibrosis i.e. Post PV-MF and Post ET-MF. Out of the 41 PMF patient 2 patients had MPL gene variation, while one of the Post ET –MF had a MPL gene variation. Forty eight (96%) were positive for JAK2 mutation. Five patients who had MPL mutation also showed JAK 2 mutation. Two of the MPL positive patients were also positive for JAK2 mutation.
Conclusion: We reported rate of recurrence of JAK2 mutation in 96% of the cases and MPL exon 10 mutations in 6% of the cases.
Keywords: JAK2, MPL, Myeloproliferative neoplasms.
Title: Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
Description:
Introduction: BCR-ABL1-negative myeloproliferative disorders are a sub-group of myeloproliferative neoplasms (MPNs) that consist of polycythemia Vera (PV), Essential thrombocythemia (ET) and Primary Myelofibrosis (PMF).
Over the past decade, the morphological and clinical division of myeloproliferative neoplasms (MPN) has changed to a classification that describes the molecular heterogeneity and is unique to this subgroup of haematological malignancies.
This includes alterations in Janus kinase 2 (JAK2), and MPL genes.
Objective: To determine the frequency of JAK2 (p.
V617F) and MPL (p.
W515L) mutation in primary myelofibrosis in KPK province of Pakistan.
Methodology: Fifty patients with PMF were enrolled in the study.
JAK2 mutation status was determined using allele specific primers and MPL mutation was detected by direct Sanger sequencing technique.
The data was analyzed using BioEdit by aligning the sequence data with reference genome hg19 assembly.
Results: Among 50 patients, 41 patients were diagnosed with PMF, while 9 patients had secondary myelofibrosis i.
e.
Post PV-MF and Post ET-MF.
Out of the 41 PMF patient 2 patients had MPL gene variation, while one of the Post ET –MF had a MPL gene variation.
Forty eight (96%) were positive for JAK2 mutation.
Five patients who had MPL mutation also showed JAK 2 mutation.
Two of the MPL positive patients were also positive for JAK2 mutation.
Conclusion: We reported rate of recurrence of JAK2 mutation in 96% of the cases and MPL exon 10 mutations in 6% of the cases.
Keywords: JAK2, MPL, Myeloproliferative neoplasms.
Related Results
MPL p.S204P Is a Recurrent Mutation in Essential Thrombocythemia
MPL p.S204P Is a Recurrent Mutation in Essential Thrombocythemia
Abstract
Introduction: The JAK2 p.V617F, MPL p.W515K/L and CALR indels occur in a mutually exclusive pattern in 80-90% of cases with Essential Thrombocythemia (ET), ...
TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL
TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL
Chronic myeloid leukemia (CML) is a hematopoietic malignancy caused by the BCR-ABL fusion gene. Although tyrosine kinase inhibitors (TKIs) targeting the oncoprotein BCR-ABL have dr...
The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia
The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia
Chronic myeloid leukemia (CML) and 30% of adult acute lymphatic leukemia (ALL) are characterized by the Philadelphia chromosome (Ph+), having a (9;22) chromosomal translocation. Th...
Development of High Throughput PCR-Invader Assay to Detect the JAK2 V617F Mutation in Japanese Myeloproliferative Disorders
Development of High Throughput PCR-Invader Assay to Detect the JAK2 V617F Mutation in Japanese Myeloproliferative Disorders
Abstract
The classic myeloproliferative disorders (MPD) of polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) are hematopoieti...
Polycythemia Vera with Multiple Clones Carrying Different Mutations (L611V, V617F, L611V/V617F) in Exon 14 of JAK2.
Polycythemia Vera with Multiple Clones Carrying Different Mutations (L611V, V617F, L611V/V617F) in Exon 14 of JAK2.
Abstract
Abstract 3908
Poster Board III-844
Background
In more than 95% of cases, Polycythemia ver...
Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia
Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia
Abstract
INTRODUCTION:
Mutations in Janus Kinase (JAK2) occur in <5% of Acute Myelogenous Leukemia (AML) cases and...
Molecular Predictors for the Response to Nilotinib Treatment After Acquired Imatinib Failure In Ph+ Chronic Myeloid Leukemia
Molecular Predictors for the Response to Nilotinib Treatment After Acquired Imatinib Failure In Ph+ Chronic Myeloid Leukemia
Abstract
Abstract 2283
Introduction:
A switch to the 2nd generation tyrosine kinase inhibitor nilotinib has been ...
Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol
Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol
Abstract
Introduction: BCR-ABL mutations are the major background players in manifestation of resistance to all FDA approved tyrosine kinase inhibitors (TKIs) includ...

